HER2 Support Group Forums - View Single Post - Purged Circulating Tumor Cells (CTCs) From Met Breast Cancer (Phase II, <60 yrs)

Rich66 · 10-18-2009, 01:39 PM

http://clinicaltrials.gov/ct2/show/s...ow_desc=Y#desc

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
This study is currently recruiting participants.
Verified by M.D. Anderson Cancer Center, May 2009
First Received: January 29, 2007 Last Updated: May 27, 2009 History of Changes
Sponsored by: M.D. Anderson Cancer Center
Information provided by: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: NCT00429182

Purpose Primary Objectives:

To determine whether high-dose chemotherapy (HDCT) with purged autologous stem cell products will reduce the presence of circulating tumor cells (CTCs) among metastatic breast cancer (MBC) patients after receiving high-dose chemotherapy autologous hematopoietic stem cell transplantation.
To determine whether reduction of CTCs will correlate with prolonged progression-free survival (PFS).

Secondary Objectives:

To determine whether reduction of CTCs will correlate with prolonged overall survival (OS).
To characterize the biology of CTC.

Condition Intervention Phase Breast Cancer
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Stem Cell Transplant
Phase II

Study Type: Interventional Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Official Title: Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients

10-18-2009, 01:39 PM	#1
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Purged Circulating Tumor Cells (CTCs) From Met Breast Cancer (Phase II, <60 yrs) http://clinicaltrials.gov/ct2/show/s...ow_desc=Y#desc Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer This study is currently recruiting participants. Verified by M.D. Anderson Cancer Center, May 2009 First Received: January 29, 2007 Last Updated: May 27, 2009 History of Changes Sponsored by: M.D. Anderson Cancer Center Information provided by: M.D. Anderson Cancer Center ClinicalTrials.gov Identifier: NCT00429182 Purpose Primary Objectives: To determine whether high-dose chemotherapy (HDCT) with purged autologous stem cell products will reduce the presence of circulating tumor cells (CTCs) among metastatic breast cancer (MBC) patients after receiving high-dose chemotherapy autologous hematopoietic stem cell transplantation. To determine whether reduction of CTCs will correlate with prolonged progression-free survival (PFS). Secondary Objectives: To determine whether reduction of CTCs will correlate with prolonged overall survival (OS). To characterize the biology of CTC. Condition Intervention Phase Breast Cancer Drug: Carboplatin Drug: Cyclophosphamide Drug: Thiotepa Procedure: Stem Cell Transplant Phase II Study Type: Interventional Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study Official Title: Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients